Connect with us

MAM

Adani declares victory over Hindenburg storm as profits soar in letter to shareholders

Published

on

MUMBAI: Gautam Adani has emerged from his regulatory bunker swinging, declaring the Hindenburg Research controversy a “defining inflection point” that strengthened rather than weakened his sprawling business empire.

In a defiant letter to shareholders, the Indian billionaire framed last week’s Securities and Exchange Board of India (Sebi)  clearance as complete vindication, proclaiming “truth has prevailed” after nearly two years of scrutiny following the short-seller’s damning January 2023 report.

The Adani Group chairman marshalled impressive financial firepower to support his narrative of resilience. Portfolio EBITDA rocketed from Rs 57,205 crore in FY23 to Rs 89,806 crore in FY25—a staggering 57 per cent absolute growth representing a two-year compound annual growth rate of 25 per cent.

Advertisement

Asset expansion proved equally dramatic, with gross block swelling from Rs 4,12,318 crore to Rs 6,09,133 crore over the same period. That Rs two lakh crore addition marks a 48 per cent surge whilst the group battled accusations of accounting manipulation and stock price inflation.

Adani positioned his conglomerate’s infrastructure achievements as proof of substance over speculation. The group commissioned India’s first container trans shipment port at Vizhinjam, added six gigawatts of renewable capacity including the world’s largest single-location renewable project at Khavda, and completed what it claims is the world’s largest copper smelter.

The rhetoric veered between wounded pride and renewed ambition. Hindenburg’s assault wasn’t merely corporate criticism, Adani argued, but “a direct challenge to the audacity of Indian enterprises to dream on a global scale.” The implication: attacking Adani amounted to attacking India itself.

Advertisement

Looking forward, the chairman promised to “further strengthen governance standards,” “accelerate innovation and sustainability,” and “double down on nation building”—language that suggests the controversy has hardly dented his expansionist appetites.

The letter’s tone reflects broader themes in Indian corporate culture, where business leaders frequently cast commercial success in nationalist terms. For Adani, surviving Hindenburg’s onslaught becomes not just corporate vindication but validation of India’s global ambitions.

Whether Sebi’s clearance truly closes the book on governance questions remains to be seen. But Adani’s defiant missive makes clear he views the storm as survived rather than merely weathered, with ambitious expansion plans intact.

Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

MAM

Beacon Group appoints Dr Rajesh Patel as Group CEO

36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.

Published

on

MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.

In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.

The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.

Advertisement

Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.

For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.

Advertisement
Continue Reading

Advertisement News18
Advertisement
Advertisement Whtasapp
Advertisement Year Enders

Indian Television Dot Com Pvt Ltd

Signup for news and special offers!

Copyright © 2026 Indian Television Dot Com PVT LTD